Literature DB >> 447479

Citrate in daily and fasting urine: results of controls, patients with recurrent idiopathic calcium urolithiasis, and primary hyperparathyroidism.

P O Schwille, D Scholz, M Paulus, W Engelhardt, A Sigel.   

Abstract

In three groups--patients with recurrent calcium urolithiasis (RCU), patients with primary hyperparathyroidism (pHPT), and healthy controls--citrate was measured enzymatically in 24 and in 2-hr urine after an overnight fast. Citrate excretion per 24 hr was significantly lower in RCU than in age and sex matched controls, whereas there was no significant difference in citrate excretion in urines from the 2-hr morning collection. In pHPT citrate was also lower than in controls and fell within the range of RCU of comparable age. Both categories of urines (24 and 2hr) have in common the characteristic that the actual citrate concentration is lower by 50 per cent in RCU and pHPT than in controls, mainly as a result of the higher urine volume. Correction of citrate for creatinine does not disclose further differences among the populations studied but conversely hampers exact interpretation of urinary citrate in the absence of strict separation of individuals according to sex and age. From these data we conclude that (i) a low excretion and concentration of urinary citrate is detectable in calcium lithiasis and may contribute to a deficiency in inhibitory activity against nucleating processes in stone-forming urine; and (ii) the differences in urinary citrate elicited in samples of 24 and 2-hr morning urine are of unknown origin and merit further investigations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 447479

Source DB:  PubMed          Journal:  Invest Urol        ISSN: 0021-0005


  11 in total

1.  On the relation between citrate and calcium in normal and stone-former subjects.

Authors:  A Conte; P Roca; M Gianotti; F Grases
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

Review 2.  Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation.

Authors:  R L Ryall
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

3.  On the relation between citrate and calcium in normal and stone-former subjects.

Authors:  A Conte; P Roca; M Gianotti; F Grases
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

4.  Mineral metabolism during prolonged oral calcium substitution after jejuno-ileal bypass for morbid obesity.

Authors:  D Scholz; P O Schwille; B Husemann; T Herzog; H W Schley; C Morzinietz; A Sigel
Journal:  Klin Wochenschr       Date:  1982-08

5.  Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium citrate administered over the short-, medium- and long-term medication of male stone patients.

Authors:  P O Schwille; U Herrmann; C Wolf; I Berger; R Meister
Journal:  Urol Res       Date:  1992

6.  Gestational urinary hyperthiosulfaturia protects hypercalciuric normal pregnant women from nephrolithiasis.

Authors:  Hippocrates Yatzidis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

7.  Primary hyperparathyroidism in Taiwan: clinical features and prevalence in a single-center experience.

Authors:  Han-Hsiang Chen; Yu-Wei Chen; Chih-Jen Wu
Journal:  Endocrine       Date:  2010-03-09       Impact factor: 3.633

8.  The effects of citrate and urine on calcium oxalate crystal aggregation.

Authors:  H G Tiselius; A M Fornander; M A Nilsson
Journal:  Urol Res       Date:  1993

9.  Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium sodium citrate administered as short-, medium- and long-term to male stone patients.

Authors:  U Herrmann; P O Schwille; H Schwarzlaender; I Berger; G Hoffmann
Journal:  Urol Res       Date:  1992

10.  Effects of a cation exchange resin on intestinal calcium absorption and urinary calcium in calcium stone formers.

Authors:  D Scholz; P O Schwille; T Herzog; A Sigel
Journal:  Urol Res       Date:  1981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.